Drug interaction between gefitinib and warfarin.
Gefitinib is a synthetic, oral anilinoquinazoline specifically designed to inhibit the epidermal growth factor receptor tyrosine kinase, and is the first targeted drug to demonstrate reproducible activity in non-small cell lung cancer patients who do not respond to platinum-based chemotherapy. In this report, we present two cases of an interaction between gefitinib and warfarin which has not been reported previously. Because of the potentially serious consequences of this interaction, close monitoring of the International Normalized Ratio and warfarin dosage adjustment are recommended for patients receiving warfarin together with gefitinib.
Onoda
Sayaka
S
Department of Respiratory Medicine, Kitasato University School of Medicine, 1-15-1 Kitasato, Sagamihara, Kanagawa 228-0022, Japan.
Mitsufuji
Hisashi
H
Yanase
Nobuo
N
Ryuge
Shinichiro
S
Kato
Emi
E
Wada
Mayumi
M
Ishii
Kaori
K
Hagiri
Shintaro
S
Yamamoto
Michiko
M
Yokoba
Masanori
M
Yanaihara
Tomoko
T
Kuboto
Masaru
M
Takada
Nobukazu
N
Katagiri
Masato
M
Abe
Tadashi
T
Tanaka
Naohiko
N
Kobayashi
Hirosuke
H
Masuda
Noriyuki
N
D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004347:Drug Interactions; D004357:Drug Synergism; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D011799:Quinazolines / Q000008:administration & dosage / Q000494:pharmacology*; D013927:Thrombosis / Q000188:drug therapy; D014859:Warfarin / Q000008:administration & dosage / Q000494:pharmacology*
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D014859:Warfarin; D066246:ErbB Receptors; D000077156:Gefitinib